Rigel Pharmaceuticals | RIGL - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agenus USD 10.56M 13.04M 2025-12
Amgen USD 1.58B 354M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 5.06B 455M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Celldex Therapeutics USD 7.84M 1.21M 2025-12
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 151M 21M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
MacroGenics USD 7.94M 1.96M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Veracyte USD 43.31M 8.43M 2025-12